SCHEMBL706497

SCHEMBL706497

O=C(ON1C(=O)CC(S(=O)(=O)O)C1=O)C1CCC(CN2C(=O)C=CC2=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL45106 0.93
SCHEMBL4620757 0.93
SCHEMBL22635959 0.93
SCHEMBL2810989 0.92
SCHEMBL29406614 0.92
SCHEMBL15940395 0.88
SCHEMBL16448969 0.86
SCHEMBL1422833 0.85
SCHEMBL17735697 0.83 ALDH1A1 (0.30)
SCHEMBL18344257 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669237-B2 Biodegradable immunomodulatory formulations and methods for use thereof DYNAVAX TECHNOLOGIES CORPORATION (US) 2014-03-11 US disclosed
US-20120121622-A1 BIODEGRADABLE IMMUNOMODULATORY FORMULATIONS AND METHODS FOR USE THEREOF DYNAVAX TECHNOLOGIES CORPORATION (US) 2012-05-17 US disclosed
US-8124590-B2 Biodegradable immunomodulatory formulations and methods for use thereof DYNAVAX TECHNOLOGIES CORPORATION (US) 2012-02-28 US disclosed
US-20110038896-A1 Biodegradable immunomodulatory formulations and methods for use thereof DYNAVAX TECHNOLOGIES CORPORATION (US) 2011-02-17 US disclosed
EP-1261378-B1 BIODEGRADABLE IMMUNOMODULATORY FORMULATIONS AND METHODS FOR USE THEREOF DYNAVAX TECH CORP (US) 2010-03-10 EP disclosed
EP-1261377-B1 IMMUNOMODULATORY FORMULATIONS AND METHODS FOR USE THEREOF DYNAVAX TECH CORP (US) 2009-09-02 EP disclosed
EP-2067487-A2 Immunomodulatory formulations and methods for use thereof Dynavax Technologies Corporation (US) 2009-06-10 EP disclosed
US-20070258994-A1 Immunomodulatory formulations and methods for use thereof DYNAVAX TECHNOLOGIES CORPORATION 2007-11-08 US disclosed
US-7250403-B2 Biodegradable immunomodulatory formulations and methods for use thereof DYNAVAX TECHNOLOGIES CORPORATION (US) 2007-07-31 US disclosed
US-7183111-B2 Immunomodulatory formulations and methods for use thereof DYNAVAX TECHNOLOGIES CORPORATION (US) 2007-02-27 US disclosed
US-7129222-B2 Immunomodulatory formulations and methods for use thereof DYNAVAX TECHNOLOGIES CORPORATION (US) 2006-10-31 US disclosed
US-20030129251-A1 Biodegradable immunomodulatory formulations and methods for use thereof DYNAVAX TECHNOLOGIES CORPORATION 2003-07-10 US disclosed
US-20030059773-A1 Immunomodulatory formulations and methods for use thereof DYNAVAX TECHNOLOGIES CORPORATION 2003-03-27 US disclosed
US-20030022852-A1 Biodegradable immunomodulatory formulations and methods for use thereof DYNAVAX TECHNOLOGIES CORPORATION 2003-01-30 US disclosed
EP-1261377-A2 IMMUNOMODULATORY FORMULATIONS AND METHODS FOR USE THEREOF Dynavax Technologies Corporation (US) 2002-12-04 EP disclosed
EP-1261378-A2 BIODEGRADABLE IMMUNOMODULATORY FORMULATIONS AND METHODS FOR USE THEREOF Dynavax Technologies Corporation (US) 2002-12-04 EP disclosed
US-20020055477-A1 Immunomodulatory formulations and methods for use thereof DYNAVAX TECHNOLOGIES CORPORATION 2002-05-09 US disclosed
WO-2001068144-A2 BIODEGRADABLE IMMUNOMODULATORY FORMULATIONS AND METHODS FOR USE THEREOF DYNAVAX TECHNOLOGIES CORPORATION (US) 2001-09-20 WO disclosed
WO-2001068143-A2 IMMUNOMODULATORY FORMULATIONS AND METHODS FOR USE THEREOF DYNAVAX TECHNOLOGIES CORPORATION (US) 2001-09-20 WO disclosed